OCT2013, AN ISCHAEMIA-ACTIVATED ANTIARRHYTHMIC PRODRUG, DEVOID OF THE SYSTEMIC SIDE EFFECTS OF LIDOCAINE.

Louise M HeskethMarkus B SikkelLaura Mahoney-SanchezFrancesca MazzacuvaRasheda A ChowdhuryKonstantinos N TzortzisJahn FirthJames WinterKenneth T MacLeodStefan OgrodzinskiCatherine D E WilderLaurence H PattersonNicholas S PetersMichael J Curtis

Published in: British journal of pharmacology (2021)

OCT2013 is inactive but is bioreduced locally in ischaemic myocardium to lidocaine, acting as an ischaemia-activated and ischaemia-selective antiarrhythmic prodrug with a large therapeutic index, mimicking lidocaine's benefit without adversity.

Keyphrases

optical coherence tomography
cancer therapy
diabetic retinopathy
catheter ablation
optic nerve
drug induced